Overview Press Releases Events and Presentations Financials and Filings Stock Information Corporate Governance FAQs Email Alerts Madrigal press releases are available below. Search them by keyword or browse by date. Year None202420232022202120202019201820172016 February 28, 2024 Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer February 28, 2024 Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results February 21, 2024 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) February 8, 2024 Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine February 6, 2024 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) January 29, 2024 Madrigal Pharmaceuticals Announces Additions to Its Leadership Team January 22, 2024 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) January 4, 2024 Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG Annual Conference January 3, 2024 Madrigal Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference Pagination Previous page Page 1 Current page 2
Madrigal press releases are available below. Search them by keyword or browse by date. Year None202420232022202120202019201820172016 February 28, 2024 Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer February 28, 2024 Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results February 21, 2024 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) February 8, 2024 Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine February 6, 2024 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) January 29, 2024 Madrigal Pharmaceuticals Announces Additions to Its Leadership Team January 22, 2024 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) January 4, 2024 Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG Annual Conference January 3, 2024 Madrigal Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference Pagination Previous page Page 1 Current page 2
February 28, 2024 Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
February 21, 2024 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
February 8, 2024 Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine
February 6, 2024 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
January 22, 2024 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
January 4, 2024 Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG Annual Conference
January 3, 2024 Madrigal Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference